Axon Enterprise, Inc $AXON Holdings Raised by Annis Gardner Whiting Capital Advisors LLC

Annis Gardner Whiting Capital Advisors LLC increased its stake in Axon Enterprise, Inc (NASDAQ:AXON) by 14,650.0% during the third quarter, HoldingsChannel reports. The firm owned 2,655 shares of the biotechnology company’s stock after acquiring an additional 2,637 shares during the period. Annis Gardner Whiting Capital Advisors LLC’s holdings in Axon Enterprise were worth $1,905,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of AXON. New York State Common Retirement Fund lifted its stake in Axon Enterprise by 2.1% during the third quarter. New York State Common Retirement Fund now owns 38,639 shares of the biotechnology company’s stock valued at $27,729,000 after buying an additional 800 shares in the last quarter. AustralianSuper Pty Ltd raised its holdings in shares of Axon Enterprise by 2.2% during the third quarter. AustralianSuper Pty Ltd now owns 82,779 shares of the biotechnology company’s stock valued at $59,406,000 after acquiring an additional 1,806 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Axon Enterprise by 11.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 34,381 shares of the biotechnology company’s stock valued at $24,673,000 after acquiring an additional 3,555 shares during the period. Ballentine Partners LLC lifted its position in shares of Axon Enterprise by 4.1% in the 3rd quarter. Ballentine Partners LLC now owns 1,143 shares of the biotechnology company’s stock valued at $820,000 after acquiring an additional 45 shares in the last quarter. Finally, Valeo Financial Advisors LLC boosted its stake in Axon Enterprise by 16.2% in the 3rd quarter. Valeo Financial Advisors LLC now owns 1,147 shares of the biotechnology company’s stock worth $823,000 after purchasing an additional 160 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Down 9.9%

Shares of Axon Enterprise stock opened at $549.86 on Thursday. The firm has a market cap of $43.39 billion, a price-to-earnings ratio of 174.01, a P/E/G ratio of 19.21 and a beta of 1.41. The stock has a 50-day simple moving average of $579.31 and a 200-day simple moving average of $672.62. Axon Enterprise, Inc has a 52-week low of $469.24 and a 52-week high of $885.91. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The firm had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The company’s quarterly revenue was up 30.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.45 EPS. On average, equities research analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

AXON has been the topic of several research analyst reports. UBS Group lowered their price objective on shares of Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Barclays lowered their price target on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Wall Street Zen lowered Axon Enterprise from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. TD Cowen reissued a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, November 5th. Finally, Piper Sandler lowered their target price on Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Fourteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Axon Enterprise has an average rating of “Moderate Buy” and an average target price of $805.71.

Insider Activity at Axon Enterprise

In other news, CFO Brittany Bagley sold 2,500 shares of the firm’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $610.00, for a total transaction of $1,525,000.00. Following the transaction, the chief financial officer owned 91,092 shares in the company, valued at approximately $55,566,120. This trade represents a 2.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jeffrey C. Kunins sold 1,797 shares of the company’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $539.23, for a total transaction of $968,996.31. Following the completion of the sale, the insider owned 83,485 shares of the company’s stock, valued at $45,017,616.55. This represents a 2.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 60,540 shares of company stock worth $34,684,738 over the last quarter. 5.70% of the stock is currently owned by corporate insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.